Special considerations for biologic medications in pediatric ulcerative colitis-Reference-Cited by-同舟云学术

Special considerations for biologic medications in pediatric ulcerative colitis

Published:2019-10-29 Issue:4 Volume:20 Page:429-435
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Jerger Logan¹,Hyams Jeffrey S.¹

Affiliation:

1. Division of Digestive Diseases, Hepatology, and Nutrition, Connecticut Children’s Medical Center, University of Connecticut School of Medicine, Hartford, USA

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1685492

Reference61 articles.

1. The global burden of IBD: from 2015 to 2025

2. Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends

3. Antibiotic use and inflammatory bowel diseases in childhood

4. Diet as a risk factor for the development of ulcerative colitis

5. Hypothesis: Increased consumption of emulsifiers as an explanation for the rising incidence of Crohn's disease

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023;Intestinal Research;2024-07-31

2. The Evolving Effectiveness of Biologics in Avoiding Surgery in Children With Ulcerative Colitis: At what Nutritional Cost?;The American Surgeon™;2023-03-04

3. Evidence for the butyrate metabolism as key pathway improving ulcerative colitis in both pediatric and adult patients;Bioengineered;2021-01-01